Clinical Trial

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

Study acronym: CARTemis-1
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells. To overcome some of the potential limitations of this therapy, a new and optimized Anti-BCMA CAR-T has been developed, with the aim of using it in patients with MM who relapse after Allogeneic Haematopoietic Haematopoietic Progenitor. This trial is a prospective phase I/II trial with a 3+3 design. Once Dose Limiting Toxicity is identified, Phase II will begin to assess the efficacy of the procedure.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-01; most recent amendment 2024-05-13.
Trial Details
NCT Number NCT05982275
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions Multiple Myeloma, Allogeneic Stem Cell Transplantation
Enrollment 25 participants
Start Date 2024-12-30
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-14